PYC Therapeutics Limited (PYCXF) Stock Statistics & Valuation Metrics

PYC Therapeutics Limited has a market cap or net worth of $1.14B. The enterprise value is $723.08M.

PYC Therapeutics Limited has 983,510,440 shares outstanding. The number of shares has decreased by -2.65% in one year.

PYC Therapeutics Limited’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -16.84%.

The current PE Ratio of PYC Therapeutics Limited is ―. PYC Therapeutics Limited’s PEG ratio is -0.01.

In the last 12 months, PYC Therapeutics Limited had revenue of 23.49M and earned -50.30M in profits. Earnings per share was -0.10.

In the last 12 months, operating cash flow was -65.75M and capital expenditures -463.80K, giving a free cash flow of -66.22M billion.

PYC Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―

PYC Therapeutics Limited upcoming earnings date is ―, ―.

PYC Therapeutics Limited as a current ratio of 14.41, with Debt / Equity ratio of 0.86%

In the past 12 months, PYC Therapeutics Limited has paid -23.49M in taxes.

PYC Therapeutics Limited EV to EBITDA ratio is -9.43, with an EV/FCF ratio of -9.49.

PYC Therapeutics Limited has $120.69M in cash and marketable securities with $1.26M in debt, giving a net cash position of $119.43M billion.

Gross margin is 97.40%, with operating margin of -228.26%, and net profit margin of -214.11%.

The average price target for PYC Therapeutics Limited is $1.99, which is 11.43% higher than the current price. The consensus rating is Moderate Buy